201 related articles for article (PubMed ID: 34331562)
1. Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome.
Gao XM; Yu YY; Zhao H; Cai H; Zhang L; Cao XX; Zhou DB; Li J
Ann Hematol; 2021 Nov; 100(11):2755-2761. PubMed ID: 34331562
[TBL] [Abstract][Full Text] [Related]
2. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome.
Li J; Huang XF; Cai QQ; Wang C; Cai H; Zhao H; Zhang L; Cao XX; Gale RP; Zhou DB
Am J Hematol; 2018 Jun; 93(6):803-809. PubMed ID: 29603764
[TBL] [Abstract][Full Text] [Related]
3. Skin Responses in Newly Diagnosed Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome After Therapy With Low-Dose Lenalidomide Plus Dexamethasone.
Gao Y; Zhang S; Yang L; Li J; Liu Y; Wang T
Front Immunol; 2021; 12():681360. PubMed ID: 34025681
[TBL] [Abstract][Full Text] [Related]
4. [POEMS syndrome. An interdisciplinary clinical challenge].
Braun SA; Albrecht P; Methner A; Hanneken S
Hautarzt; 2011 Oct; 62(10):722-5. PubMed ID: 21915731
[TBL] [Abstract][Full Text] [Related]
5. Effective induction therapy with subcutaneous administration of bortezomib for newly diagnosed POEMS syndrome: a case report and a review of the literature.
Zeng K; Yang JR; Li J; Wei Q; Yang YM; Liu T; Niu T
Acta Haematol; 2013; 129(2):101-5. PubMed ID: 23171959
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of POEMS syndrome with bortezomib and dexamethasone, combined with radiotherapy, and followed by autologous stem cell transplantation.
Ishii Y; Yamazaki E; Ishiyama Y; Yamamoto E; Hattori Y; Hagihara M; Tomita N; Ishigatsubo Y
Int J Hematol; 2013 Dec; 98(6):723-8. PubMed ID: 24166587
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of POEMS syndrome with lenalidomide and dexamethasone].
Goto A; Iyama S; Sugama Y; Yoshida M; Ibata S; Tatekoshi A; Fujita C; Kikuchi S; Ikeda H; Murase K; Takada K; Kato J; Kobune M
Rinsho Ketsueki; 2019; 60(4):308-313. PubMed ID: 31068561
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial.
Misawa S; Sato Y; Katayama K; Nagashima K; Aoyagi R; Sekiguchi Y; Sobue G; Koike H; Yabe I; Sasaki H; Watanabe O; Takashima H; Nishizawa M; Kawachi I; Kusunoki S; Mitsui Y; Kikuchi S; Nakashima I; Ikeda S; Kohara N; Kanda T; Kira J; Hanaoka H; Kuwabara S;
Lancet Neurol; 2016 Oct; 15(11):1129-37. PubMed ID: 27496680
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome.
Kuwabara S; Misawa S; Kanai K; Sawai S; Hattori T; Nishimura M; Nakaseko C
J Neurol Neurosurg Psychiatry; 2008 Nov; 79(11):1255-7. PubMed ID: 18469028
[TBL] [Abstract][Full Text] [Related]
10. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome.
Li J; Zhang W; Jiao L; Duan MH; Guan HZ; Zhu WG; Tian Z; Zhou DB
Blood; 2011 Jun; 117(24):6445-9. PubMed ID: 21393478
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy.
He T; Zhao A; Zhao H; Cai H; Feng J; Zhang L; Cao X; Zhou D; Li J
Ann Hematol; 2019 Mar; 98(3):735-743. PubMed ID: 30612232
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study.
Misawa S; Sato Y; Katayama K; Hanaoka H; Sawai S; Beppu M; Nomura F; Shibuya K; Sekiguchi Y; Iwai Y; Watanabe K; Amino H; Ohwada C; Takeuchi M; Sakaida E; Nakaseko C; Kuwabara S
BMJ Open; 2015 Nov; 5(11):e009157. PubMed ID: 26560063
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients.
Royer B; Merlusca L; Abraham J; Musset L; Haroche J; Choquet S; Leleu X; Sebban C; Decaux O; Galicier L; Roussel M; Recher C; Banos A; Guichard I; Brisseau JM; Godmer P; Hermine O; Deplanque G; Facon T; Asli B; Leblond V; Fermand JP; Marolleau JP; Jaccard A
Am J Hematol; 2013 Mar; 88(3):207-12. PubMed ID: 23335406
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure.
Li J; Zhang W; Kang WY; Cao XX; Duan MH; Zhou DB
Leuk Lymphoma; 2012 Dec; 53(12):2527-9. PubMed ID: 22553961
[No Abstract] [Full Text] [Related]
15. Efficacy of bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed POEMS syndrome patients.
Fang F; Lan XX; Hu RH; Hui WH; Zhao H; Guo YX; Ji BX; Liu HJ; Su L; Sun WL
Ther Adv Neurol Disord; 2024; 17():17562864231219151. PubMed ID: 38288324
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial.
Suichi T; Misawa S; Nagashima K; Sato Y; Iwai Y; Katayama K; Sekiguchi Y; Shibuya K; Amino H; Suzuki YI; Tsuneyama A; Nakamura K; Kuwabara S
Intern Med; 2020 May; 59(9):1149-1153. PubMed ID: 32009091
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial.
Nozza A; Terenghi F; Gallia F; Adami F; Briani C; Merlini G; Giordano L; Santoro A; Nobile-Orazio E
Br J Haematol; 2017 Dec; 179(5):748-755. PubMed ID: 29048107
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes of Autologous Stem Cell Transplantation in Patients with Newly Diagnosed POEMS Syndrome.
Li AA; Gao XM; Zhao H; Shen KN; Zhang L; Cao XX; Li J
Transplant Cell Ther; 2024 Feb; 30(2):207.e1-207.e7. PubMed ID: 37931801
[TBL] [Abstract][Full Text] [Related]
19. Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.
Suichi T; Misawa S; Sekiguchi Y; Shibuya K; Nakamura K; Kano H; Aotsuka Y; Otani R; Morooka M; Tsukamoto S; Takeda Y; Mimura N; Ohwada C; Sakaida E; Kuwabara S
Intern Med; 2022; 61(17):2567-2572. PubMed ID: 36047093
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide as frontline therapy in polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome: a retrospective case series of eight patients.
Lestang E; Caristan A; Néel A; Graveleau J; Duhamel E; Masseau A; Connault J; Maisonneuve H; Le Gouill S; Blin N; Touzeau C; Moreau P; Hamidou M
Leuk Lymphoma; 2015 Jun; 56(6):1895-6. PubMed ID: 25347429
[No Abstract] [Full Text] [Related]
[Next] [New Search]
